We present the results of 2-Step generation of adaptable IMAT plans for prostate carcinoma cases. The 2-Step IMAT plans show clinical and dosimetric equivalence to the reference SmartArc™-generated VMAT plans. The 2-Step plans are adapted to inter-fractional changes of prostate-rectum geometry using 2-Step adaptation rules for a cohort of ten adaptation cases. The adapted 2-Step IMAT plans show statistically significant improvement (Wilcoxon 1-tail p < 0.05) of target coverage and of rectum sparing when compared to isocenter relocated plans.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1088/0031-9155/59/8/1947 | DOI Listing |
Rep Pract Oncol Radiother
March 2024
Department of Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland.
Background: The purpose was to assess the impact of irradiation technique type and beam energy on the mixed radiation field around the medical linear accelerator (linac) in terms of radiation quality and related radiation protection quantities.
Materials And Methods: Seven radiotherapeutic plans with Alderson-Rando anthropomorphic phantom [different techniques: conventional three-dimensional conformal radiotherapy (3D-CRT), intensity-modulated radiotherapy (IMRT) and intensity modulated arc therapy (IMAT), different beams: 6 MV or 18 MV, and their arrangements) were prepared for the case of prostate malignancy. Recombination chambers REM-2 and GW2 were positioned on the treatment couch 100 cm from the beam axis at the height of the isocentre.
Clin Oncol (R Coll Radiol)
June 2024
Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK. Electronic address:
Background And Purpose: For high-risk neuroblastoma, planning target volume coverage is often compromised to respect adjacent kidney tolerance. This trial investigated whether intensity-modulated arc radiotherapy techniques (IMAT) could facilitate dose escalation better than conventional techniques.
Materials And Methods: Children with high-risk abdominal neuroblastoma referred for radiotherapy to the primary tumour site and involved regional lymph nodes were randomised to receive either standard dose (21 Gy in 14 fractions) or escalated dose (36 Gy in 24 fractions) radiotherapy.
Front Oncol
January 2023
Department of Radiation Therapy, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Purpose: This study aimed to assess interfraction stability of the delivered dose distribution by exhale-gated volumetric modulated arc therapy (VMAT) or intensity-modulated arc therapy (IMAT) for lung cancer and to determine dominant prognostic dosimetric and geometric factors.
Methods: Clinical target volume (CTV) from the planning CT was deformed to the exhale-gated daily CBCT scans to determine CTV, treated by the respective dose fraction. The equivalent uniform dose of the CTV was determined by the power law (EUD) and cell survival model (EUD) as effectiveness measure for the delivered dose distribution.
J Appl Clin Med Phys
November 2022
Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Purpose: We report on a dosimetrical study of three patient positions (supine, prone dive, and prone crawl) and four irradiation techniques for whole-breast irradiation (WBI): wedged-tangential fields (W-TF), tangential-field intensity-modulated radiotherapy (TF-IMRT), multi-beam IMRT (MB-IMRT), and intensity-modulated arc therapy (IMAT). This is the first study to evaluate prone crawl positioning in WBI and the first study to quantify dosimetrical and anatomical differences with prone dive positioning.
Methods: We analyzed five datasets with left- and right-sided patients (n = 51).
N Engl J Med
February 2022
From IMAT Oncomédica, Monteria, Colombia (A.J.B.); the Department of Public Health, Hospital de Clínicas, Federal University of Paraná, Curitiba, Brazil (M.M.G.S.); Jongaie Research, Pretoria, South Africa (D.B.M.); Medical Research Institute, St. Petersburg, Russia (E.K.); Advanced Research for Health Improvement, Immokalee, FL (A.G.); Lung Center of the Philippines, Quezon City, Philippines (V.D.R.); Hospital Universitario La Paz, IdiPAZ, Madrid (A.M.-Q.); Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem (Y.C.); and Merck, Kenilworth, NJ (A.W.-D., M.L.B., J.D., A. Pedley, C.A., J.S., J.A.G., H.H.S., R.T., H.W., A. Paschke, J.R.B., M.G.J., C.D.A.).
Background: New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Methods: We conducted a phase 3, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of treatment with molnupiravir started within 5 days after the onset of signs or symptoms in nonhospitalized, unvaccinated adults with mild-to-moderate, laboratory-confirmed Covid-19 and at least one risk factor for severe Covid-19 illness.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!